Overview

Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This study will compare the efficacy and safety of once daily treatment of LEO 19123 cream versus Dovonex® cream (applied twice daily) and versus LEO 19123 cream vehicle alone (applied twice daily) in subjects with psoriasis vulgaris. Subject will be treated for 4 weeks. All subjects will apply LEO 19123 cream to psoriasis lesions on the left or right side of the body and either Dovonex® cream or cream vehicle to lesions on the other side.
Phase:
Phase 2
Details
Lead Sponsor:
LEO Pharma
Treatments:
Calcipotriene